Cancer Genetics Inc, Rutherford, NJ, introduces its proprietary cervical cancer test, the FISH-based HPV-Associated Cancer Test (FHACT).
The FISH-based HPV-Associated Cancer Test (FHACT™) uses a combination of genetic markers to detect genetic abnormalities located at 3q, 5p, 20q, and chromosome 7.
A recent study concluded that these four biomarkers are associated with the severity of cervical lesions.
The findings of the study, published in the July issue of Gynecologic Oncology, support the use of FHACT™ as an aid in the screening of women with HPV-positive abnormal cervical lesions.
By identifying lesions that will progress to a higher grade versus those that will regress, FHACT™ can allow for a better triage of patients before referral for colposcopy and consequently reduce the associated health care burden, the company says.
The test can be performed directly on Pap smear or liquid based-cytology and does not require any resampling.
[Source: Cancer Genetics]
